Distribution and characteristics of androgen receptor (AR) in breast cancer among women in Addis Ababa, Ethiopia: A cross sectional study

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: WFRF:(Abebe Markos) > Distribution and ch...

LIBRIS Formathandbok (Information om MARC21)

Fältnamn	Indikatorer	Metadata
000		04633naa a2200421 4500
001		oai:DiVA.org:oru-81776
003		SwePub
008		200511s2020 \| \|\|\|\|\|\|\|\|\|\|\|000 \|\|eng\|
024	7	a https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-817762 URI
024	7	a https://doi.org/10.1371/journal.pone.02325192 DOI
040		a (SwePub)oru
041		a engb eng
042		9 SwePub
072	7	a ref2 swepub-contenttype
072	7	a art2 swepub-publicationtype
100	1	a Hadgu, Endaleu Department of Biochemistry, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia4 aut
245	1 0	a Distribution and characteristics of androgen receptor (AR) in breast cancer among women in Addis Ababa, Ethiopia :b A cross sectional study
264		c 2020-05-06
264	1	b Public Library Science,c 2020
338		a print2 rdacarrier
500		a Funding Agencies:Addis Ababa University, School of Graduate Studies, thematic research group "clinico-epidemiological characterization of breast cancer in Ethiopia" Armauer Hansen Research Institute (AHRI) AHRI from Swedish International Developmental Agency (SIDA), Sweden
520		a Evaluation of the role of androgen receptor (AR) in the biology of breast cancer is an emerging area of research. There are compelling evidences that AR expression may be used to further refine breast cancer molecular subtyping with prognostic and therapeutic implications. Many studies indicated co-expression of AR with the hormonal receptors in breast cancer has a favorable prognosis. AR is also investigated by many researchers as a potential therapeutic target in treatment of breast cancer. Studies on the frequency and distribution of AR in breast cancer among Africans is barely available. Given the heightened interest to understand its role in breast cancer, we determined AR expression and assessed its association with clinicopathological parameters among Ethiopian women. In this study, 112 newly diagnosed patient with invasive breast cancer at Tikur Anbessa Specialized Hospital were enrolled. Immunohistochemical assessment of AR, ER, PR, Ki67 and HER2 were performed using tissue microarrays (TMA) constructed from their primary tumor block. Out of the 112 participants, 91 (81%) were positive for AR expression and the remaining 21 participants (19%) were negative for AR expression. Expression of AR in ER+, HER2+ and TNBC cases were 93%, 83% and 48% respectively. Our study reveals AR is expressed in a significant number of breast cancers patients and this may indicate that breast cancers cases in Ethiopia have favorable prognosis and could benefit from progresses in AR targeted treatments. Since AR expression has important consequences on the prognosis and treatment of breast cancer, further studies with an increased number of participants is necessary to confirm our reports.
650	7	a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650	7	a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
700	1	a Seifu, Danielu Department of Biochemistry, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia4 aut
700	1	a Tigneh, Wondemagegnhuu Department of Oncology, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia4 aut
700	1	a Bokretsion, Yonasu Department of Pathology, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia4 aut
700	1	a Bekele, Abebeu Department of Surgery, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia4 aut
700	1	a Abebe, Markosu Armauer Hansen research Institute (AHRI), Addis Ababa, Ethiopia4 aut
700	1	a Sollie, Thomasu School of Medical Sciences, Örebro University, Örebro, Sweden4 aut
700	1	a Karlsson, Christina,d 1968-u Örebro universitet,Institutionen för hälsovetenskaper4 aut0 (Swepub:oru)ckn
700	1	a Karlsson, Mats G.,d 1960-u Örebro universitet,Institutionen för medicinska vetenskaper4 aut0 (Swepub:oru)mskn
710	2	a Department of Biochemistry, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopiab Department of Oncology, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia4 org
773	0	t PLOS ONEd : Public Library Scienceg 15:5q 15:5x 1932-6203
856	4	u https://doi.org/10.1371/journal.pone.0232519y Fulltext
856	4	u https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0232519&type=printable
856	4 8	u https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-81776
856	4 8	u https://doi.org/10.1371/journal.pone.0232519

Hitta via bibliotek

PLOS ONE (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...: Hadgu, Endale; Seifu, Daniel; Tigneh, Wondemag ...; Bokretsion, Yona ...; Bekele, Abebe; Abebe, Markos; visa fler...; Sollie, Thomas; Karlsson, Christ ...; Karlsson, Mats G ...; visa färre...

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Cancer och onkol ...

Artiklar i publikationen: PLOS ONE

Av lärosätet: Örebro universitet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se